Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6Thoracic 5Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Lymphoid 1Classical hematology 1Breast 1

Conditions

Pancreatic Neoplasms 1Cachexia 1Anorexia 1Anemia 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infliximab × Classical hematology × Clear all
NCT00060502 2011-05-17

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

Centocor, Inc.

Phase 2 Completed
73 enrolled
Classical hematologyGastrointestinal

Anemia, Anorexia, Cachexia, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡